摘要
目的探究肺癌肿瘤标志物在非小细胞肺癌(Non-small cell lung cancer,NSCLC)的诊断价值及临床意义。方法选取许昌市中心医院2014年10月~2016年10月49例NSCLC患者设为实验组,选取同期49例健康体检人群设为对照组。应用电化学免疫发光法检测两组肺癌肿瘤标志物水平变化情况[血清肿瘤标记物癌胚抗原(CEA)、细胞角蛋白19片段抗原(CYFRA21-1)、神经元特异性烯醇化酶(NSE)],统计其诊断敏感度、特异度及准确度。结果实验组CEA、CYFRA21-1、NSE水平均高于对照组,差异有统计学意义(P<0.05);治疗后实验组CEA、CYFRA21-1、NSE水平均低于治疗前,差异有统计学意义(P<0.05)。CEA+CYFRA21-1+NSE三项联合检测敏感度、特异度及准确度均高于CEA、CYFRA21-1、NSE单项检测,差异有统计学意义(P<0.05)。结论肺癌肿瘤标志物可用于NSCLC的诊断及预后评估,有利于提高其诊断准确度,且CEA、CYFRA21-1、NSE水平变化可为疾病发展、病情监测及预后提供重要依据。
Objective To investigate the diagnostic value of lung cancer tumor markers in non-small cell lung cancer( NSCLC) and its clinical significance. Methods Totally 49 patients with NSCLC were selected as experimental group from October 2014 to October 2016 in Xuchang Central Hospital,and selected 49 healthy subjects as the control group at the same period. Tumor markers levels in lung cancer [serum tumor markers Carcinoembryonic antigen( CEA),cytokeratin 19 fragment antigen( CYFRA21-1),neuron-specific enolase( NSE) ]were detected by electrochemical immunoluminescence assay between the two groups,and statistically analyzed its diagnostic sensitivity,specificity and accuracy. Results The levels of CEA,CYFRA21-1 and NSE in the experimental group were significantly higher than those in the control group( P〈0. 05); After treatment,the levels of CEA,CYFRA21-1 and NSE in the experimental group were significantly lower than those before treatment( P〈0. 05). Conclusion The tumor markers of lung cancer can be used in the diagnosis and prognosis of NSCLC,which is helpful to improve the diagnostic accuracy,and the changes of CEA,CYFRA21-1 and NSE levels can provide important basis for disease development,disease monitoring and prognosis.
出处
《医药论坛杂志》
2017年第6期62-64,共3页
Journal of Medical Forum